Targeting FoxO1 in traditional Chinese medicine for the treatment of diabetes

被引:0
|
作者
Liu, Yang [1 ]
Fu, Bingmei M. [2 ]
Zeng, Ye [3 ]
机构
[1] Hong Kong Polytech Univ, Hung Hom, Kowloon, Hong Kong, Peoples R China
[2] CUNY, Dept Biomed Engn, City Coll, New York, NY 10031 USA
[3] Sichuan Univ, Inst Biomed Engn, West China Sch Basic Med Sci & Forens Med, Chengdu, Sichuan, Peoples R China
关键词
FoxO1; diabetes; traditional Chinese medicine (TCM); map-ping; signaling molecule; INTRACELLULAR CALCIUM; TRANSCRIPTION; CANCER; EXPRESSION; PAEONOL;
D O I
10.14715/cmb/2023.69.12.8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Traditional Chinese medicine (TCM) encompasses treatment strategies for diabetes, which is referred to as "Consumptive Thirsty" syndrome. Recently, there has been a discovery regarding the mapping between TCM and signaling molecules, which has revealed a remarkable consistency between TCM and modern medicine from a molecular perspective. In this manuscript, we have summarized the etiology and treatment strategies for diabetes in TCM and have examined these strategies in the context of molecular mechanisms. Our review demonstrates that the targeting molecule of TCM for the treatment of diabetes is FoxO1, a trans-cription factor that plays a pivotal role in regulating gluconeogenesis and glycogenolysis. TCM ranks the development of diabetes into three stages and utilizes different herbal formulas to control FoxO1 accordin-gly. At Stage 1, TCM inhibits FoxO1 by lowering its expression in the lung. At Stage 2, TCM increases the expression of FoxO1 by suppressing its activity in the stomach. At Stage 3, TCM utilizes the famous herbal formula Liuwei Dihuang Pill to amplify the expression of FoxO1, and to enhance the concentrations of potas-sium, phosphorus, and Wnt, but to reduce the concentration of calcium. These TCM treatment strategies are in accordance with corresponding mechanisms in modern medicine.
引用
收藏
页码:44 / 51
页数:8
相关论文
共 50 条
  • [1] Targeting FoxO1 for Hypertriglyceridemia
    Kim, Dae Hyun
    Zhang, Ting
    Ringquist, Steven
    Dong, H. Henry
    CURRENT DRUG TARGETS, 2011, 12 (09) : 1245 - 1255
  • [2] Traditional Chinese medicine in the treatment of diabetes
    Zhao, Hai-Lu
    Tong, Peter C. Y.
    Chan, Juliana C. N.
    NUTRITIONAL MANAGEMENT OF DIABETES MELLITUS AND DYSMETABOLIC SYNDROME, 2006, 11 : 15 - +
  • [3] Discovery of novel FoxO1 inhibitors for the treatment of diabetes
    Johansson, Anders
    Petersson, Maria
    Fredenwall, Marlene
    Chen, Yantao
    Karlsson, Olle
    Ulander, Johan
    Peric, Alexandra
    Ericson, Elke
    Huldt, Charlotte Wennberg
    Hayes, Martin
    Norris, Tyrell
    Linden, Daniel
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [5] Diabetes: Selective FOXO1 modulation
    Crunkhorn S.
    Nature Reviews Drug Discovery, 2017, 16 (12) : 828 - 828
  • [6] FOXO1 or not FOXO1: that is the question
    Marchais, Maude
    Mangeney, Marianne
    CANCER COMMUNICATIONS, 2025, 45 (01) : 43 - 45
  • [7] Targeting FOXO1 as an option to treat obesity?
    Dansen, Tobias B.
    Kalkhoven, Eric
    CELL CYCLE, 2015, 14 (16) : 2558 - 2558
  • [8] Targeting FoxO1 with AS1842856 Suppresses Adipogenesis
    Zou, Peng
    Liu, Longhua
    Zheng, Louise
    Liu, Lu
    Stoneman, Rebecca E.
    Cho, Alicia
    Emery, Ashley
    Gilbert, Elizabeth R.
    Cheng, Zhiyong
    CELL CYCLE, 2014, 13 (23) : 3759 - 3767
  • [9] FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?
    Pandey, Anuradha
    Kumar, Goru Santosh
    Kadakol, Almesh
    Malek, Vajir
    Gaikwad, Anil Bhanudas
    CURRENT DIABETES REVIEWS, 2016, 12 (03) : 223 - 230
  • [10] Association Between FOXO1 and FOXO3 Gene Variations and Type 2 Diabetes in a Han Chinese Population
    Wu, Zhixiang
    Wang, Yuxia
    Fernandez, Francesca
    Budak, Ulvi
    Yu, Yinghua
    Yu, Shijia
    Huang, Xu-Feng
    DIABETES, 2013, 62 : A717 - A717